Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer

European Journal of Pharmacology

Volumn 591, Issue 1-3, 2008, Pages 43-51

  Liu, Hongyu ^a   Zang, Chuanbing ^a   Emde, Anna ^a   Planas Silva, Maricarmen D ^b   Rosche, Marleen ^a   Kühnl, Andrea ^a   Schulz, Carsten Oliver ^a   Elstner, Elena ^a   Possinger, Kurt ^a   Eucker, Jan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Honokiol; Lapatinib; Proliferation; Rapamycin

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ESTROGEN RECEPTOR; HONOKIOL; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MAGNOLIACEAE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGNANS; MAGNOLIA; MEDICINE, CHINESE TRADITIONAL; QUINAZOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS;

EID: 48749104995     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.026     Document Type: Article

References (30)

1. Ahn K.S., Sethi G., Shishodia S., Sung B., Arbiser J.L., and Aggarwal B.B. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol. Cancer Res. 4 (2006) 621-633
2. Altomare D.A., and Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 (2005) 7455-7464
3. Bai X., Cerimele F., Ushio-Fukai M., Waqas M., Campbell P.M., Govindarajan B., Der C.J., Battle T., Frank D.A., Ye K., Murad E., Dubiel W., Soff G., and Arbiser J.L. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J. Biol. Chem. 278 (2003) 35501-35507
4. Battle T.E., Arbiser J., and Frank D.A. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106 (2005) 690-697
5. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
6. Christgen M., and Lehmann U. MDA-MB-435: The questionable use of a melanoma cell line as a model for human breast cancer is going on. Cancer Biol. Ther. 6 (2007) 1355-1357
7. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1 (2002) 707-717
8. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., and Li F. The c-Myc target gene network. Semin. Cancer Biol. 16 (2006) 253-264
9. Fong W.F., Tse A.K., Poon K.H., and Wang C. Magnolol and honokiol enhance HL-60 human leukemia cell differentiation induced by 1,25-dihydroxyvitamin D3 and retinoic acid. Int. J. Biochem. Cell Biol. 37 (2005) 427-441
10. Ishitsuka K., Hideshima T., Hamasaki M., Raje N., Kumar S., Hideshima H., Shiraishi N., Yasui H., Roccaro A.M., Richardson P., Podar K., Le Gouill S., Chauhan D., Tamura K., Arbiser J., and Anderson K.C. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 106 (2005) 1794-1800
11. Johnston S.R., and Leary A. Lapatinib: a novel EGFR/HER-2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc.) 42 (2006) 441-453
12. Lee B., Kim C.H., and Moon S.K. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett. 580 (2006) 5177-5184
13. Liou K.T., Shen Y.C., Chen C.F., Tsao C.M., and Tsai S.K. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur. J. Pharmacol. 475 (2003) 19-27
14. Liu H., Zang C., Fenner M.H., Liu D., Possinger K., Koeffler H.P., and Elstner E. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 107 (2006) 3683-3692
15. Lo Y.C., Teng C.M., Chen C.F., Chen C.C., and Hong C.Y. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem. Pharmacol. 47 (1994) 549-553
16. Menard S., Balsari A., Casalini P., Tagliabue E., Campiglio M., Bufalino R., and Cascinelli N. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin. Cancer Res. 8 (2002) 520-525
17. Morgensztern D., and McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16 (2005) 797-803
18. Nagase H., Ikeda K., and Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med. 67 (2001) 705-708
19. Nahta R., and Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett. 232 (2006) 123-138
20. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., and Esteva F.J. Mechanisms of disease: understanding resistance to HER-2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3 (2006) 269-280
21. Normanno N., Di Maio M., De Maio E., De Luca A., de Matteis A., Giordano A., and Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12 (2005) 721-747
22. Ocana A., Cruz J.J., and Pandiella A. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am. J. Clin. Oncol. 29 (2006) 90-95
23. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
24. Tse A.K., Wan C.K., Shen X.L., Yang M., and Fong W.F. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochem. Pharmacol. 70 (2005) 1443-1457
25. Wang T., Chen F., Chen Z., Wu Y.F., Xu X.L., Zheng S., and Hu X. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J. Gastroenterol. 10 (2004) 2205-2208
26. Xu D., Lu Q., and Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett. 243 (2006) 274-280
27. Yang S.E., Hsieh M.T., Tsai T.H., and Hsu S.L. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem. Pharmacol. 63 (2002) 1641-1651
28. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev., Mol. Cell Biol. 2 (2001) 127-137
29. Zang C., Liu H., Posch M.G., Waechter M., Facklam M., Fenner M.H., Ruthardt M., Possinger K., Phillip K.H., and Elstner E. Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk. Res. 28 (2004) 387-397
30. Zhang X., Chen S., and Wang Y. Honokiol up-regulates prostacyclin synthease protein expression and inhibits endothelial cell apoptosis. Eur. J. Pharmacol. 554 (2007) 1-7